Anti-diabetic effect of a preparation of vitamins, minerals and trace elements in diabetic rats: a gender difference by Sárközy, Márta et al.
Sárközy et al. BMC Endocrine Disorders 2014, 14:72
http://www.biomedcentral.com/1472-6823/14/72RESEARCH ARTICLE Open AccessAnti-diabetic effect of a preparation of vitamins,
minerals and trace elements in diabetic rats:
a gender difference
Márta Sárközy1, Veronika Fekete1, Gergő Szűcs1, Szilvia Török1, Csilla Szűcs3, Judit Bárkányi3, Zoltán V Varga1,4,
Imre Földesi5, Csaba Csonka1,2, Csaba Kónya3, Tamás Csont1,2† and Péter Ferdinandy2,4*†Abstract
Background: Although multivitamin products are widely used as dietary supplements to maintain health or as
special medical food in certain diseases, the effects of these products were not investigated in diabetes mellitus,
a major cardiovascular risk factor. Therefore, here we investigated if a preparation of different minerals, vitamins,
and trace elements (MVT) for human use affects the severity of experimental diabetes.
Methods: Two days old neonatal Wistar rats from both genders were injected with 100 mg/kg of streptozotocin
or its vehicle to induce diabetes. At week 4, rats were fed with an MVT preparation or vehicle for 8 weeks. Well
established diagnostic parameters of diabetes, i.e. fasting blood glucose and oral glucose tolerance test were
performed at week 4, 8 and 12. Moreover, serum insulin and blood HbA1c were measured at week 12.
Results: An impaired glucose tolerance has been found in streptozotocin-treated rats in both genders at week 4.
In males, fasting blood glucose and HbA1c were significantly increased and glucose tolerance and serum insulin
was decreased at week 12 in the vehicle-treated diabetic group as compared to the vehicle-treated non-diabetic
group. All of the diagnostic parameters of diabetes were significantly improved by MVT treatment in male rats.
In females, streptozotocin treatment resulted in a less severe prediabetic-like phenotype as only glucose tolerance
and HbA1c were altered by the end of the study in the vehicle-treated diabetic group as compared to the
vehicle-treated non-diabetic group. MVT treatment failed to improve the diagnostic parameters of diabetes in
female streptozotocin-treated rats.
Conclusion: This is the first demonstration that MVT significantly attenuates the progression of diabetes in
male rats with chronic experimental diabetes. Moreover, we have confirmed that females are less sensitive to
STZ-induced diabetes and MVT preparation did not show protection against prediabetic state. This may suggest a
gender difference in the pathogenesis of diabetes.
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The rapid increase in the prevalence of diabetes mellitus
across the world gives diabetes the status of an epidemic
in the 21st century [1]. In the last decades, there was an
explosive increase in the number of people diagnosed with
diabetes worldwide due to aging as well as increasing* Correspondence: peter.ferdinandy@pharmahungary.com
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unless otherwise stated.prevalence of obesity and physical inactivity [1-3]. The
total number of people with diabetes is projected to rise
from 347 million in 2008 [4] to 552 million in 2030 [5].
Not only total energy intake and macronutrients includ-
ing carbohydrates, protein and fat, but also micronutrients
including vitamins, minerals and trace elements have ef-
fects on the severity of diabetes mellitus. Clinical studies
have shown that some individual vitamins e.g. A [6], B1
[7], B3 [8], C [9,10], D [11] and E [12], minerals e.g. cal-
cium [13], magnesium [14] and trace elements e.g. zinc
[15], chrome [16] beneficially affect the complications ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vidual vitamins, minerals and trace elements or combin-
ation of two or three components were investigated on
diabetes. Surprisingly, there is no literature data available
on the effects of multivitamin, minerals and trace ele-
ments containing preparations that can be used for hu-
man treatment in diabetes mellitus.
Regular consumption of vitamin/mineral supplements
is common in developed countries [17] to maintain gen-
eral health. In the United States, more than half of the
adult population use dietary supplements [18,19] primar-
ily in the form of multivitamins with or without minerals
[20]. In Germany, a study in 1998 reported that 18% of
men and 25% of women were regular users of multivita-
mins in a sample of population aged 18–79 years [21].
Moreover, MVT preparations appeared on the market as
medical food for diabetics; however, no literature data
supports the beneficial effect of these preparations in
preclinical or clinical studies.
Therefore, here we aimed to investigate if an MVT
preparation containing 26 different minerals, vitamins
and vitamin-like antioxidants, as well as trace elements
affects the progression of diabetes in an experimental
model of diabetes in rats.
Methods
This investigation conforms to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
(NIH Pub. No. 85–23, Revised 1996) and was approved by
the Animal Research Ethics Committee of the University
of Szeged.
Two days old neonatal male and female Wistar rats
were used in this study. Lactating females with their lit-
ters were separately housed in individually ventilated
cages (Sealsafe IVC system, Italy) and were maintained
in a temperature-controlled room with a 12:12 h light:
dark cycles for four weeks. After separation from the
mother at week 4, littermates were housed in pairs
under the same circumstances as mentioned above until
12 weeks of age. Standard rat chow (for ingredients see
Additional file 1) and tap water were supplied ad libitum
throughout the study.
Experimental protocol
Two day old neonatal male and female Wistar rats were
injected with 100 mg/kg of streptozotocin (STZ) (n = 69)
or its vehicle (ice-cold citrate buffer) (n = 38) to induce
experimental diabetes mellitus (Figure 1). Neonatal rats
were kept with the mother during the lactation period
until week 4. For lactating mothers, standard rat chow
and tap water were supplied ad libitum throughout the
study. At week 4, fasting blood glucose measurement
and an oral glucose tolerance test (OGTT) were per-
formed in order to verify the development of impairedglucose tolerance of diabetes mellitus (Figure 1) in surviv-
ing animals. In the citrate buffer-treated group, 38 animals
survived (mortality rate: 0%, n = 21 male and 17 female).
In the streptozotocin-treated group, 40 animals survived
(mortality rate: 42%, n = 20 males and 20 females). Both
non-diabetic (n = 38) and diabetic rats (n = 40) were then
fed per os via gavage (1 mL/kg, 1% methylcellulose sus-
pension) with a MVT preparation (253.3 mg/kg/day, sus-
pended in methylcellulose) (n = 9-10) to be registered as
medical food for human use (Diacomplex film-coated
tablet, Béres Pharmaceuticals, Budapest, Hungary; for con-
tent see Table 1) or its vehicle (157 mg/kg/day, suspended
in methylcellulose) (n = 8-11) for eight weeks (Figure 1).
To conform to the human daily dose of the preparation,
rat daily dose was adjusted according to the ratio of human
and rat body surface areas. Fasting blood glucose measure-
ment was performed in every second week and OGTT in
every fourth week until week 12 to monitor the effect of
multivitamin treatment on diabetes mellitus (Figure 1).
Serum insulin and hemoglobinA1c level were measured at
week 12 as well (Figure 1). To monitor the effect of dia-
betes mellitus on serum lipid levels, systemic inflamma-
tion, certain ion concentrations and activities of enzymes
requiring vitamin cofactors, serum cholesterol, triglycer-
ide, C-reactive protein (CRP), calcium, magnesium, phos-
phate and iron ion concentrations and LDH and ASAT
enzyme activities were measured in the control placebo
and diabetes placebo groups in both genders at week 12.
Blood glucose measurements and oral glucose tolerance
test (OGTT)
Rats were fasted overnight (12 h) prior to blood glucose
level measurements (week 4, 6, 8, 10 and 12) and OGTTs
(week 4, 8 and 12) in order to verify the development of
diabetes mellitus and to monitor the effect of multivitamin
treatment on diabetes. Blood samples were collected from
the saphenous vein. Blood glucose levels were measured
using Accucheck blood glucose monitoring systems
(Roche Diagnostics Corporation, USA, Indianapolis) [22,23].
OGTT was performed as follows. After measurement of
baseline glucose concentrations, glucose at 1.5 g/kg body
weight was administered via oral gavage and plasma glu-
cose levels were measured 30, 60 and 120 minutes later
and area under the curve was determined [22,23].
Hemoglobin A1c
In order to monitor the chronic effect of MVT contain-
ing preparation on diabetes mellitus, hemoglobin A1c
was measured from whole venous blood with an in vitro
test (Bio-Rad in2it System) according to the instructions
of the manufacturer. The test is based on single wave
length photometry (440 nm) to detect glycated fraction
separated from the non-glycated fraction by boronate af-
finity chromatography.
day 2
vehicle
multivitaminCONTROL(ip. vehicle on day 2)
DIABETES
(ip. streptozotocin on day 2)
4 6 8 10 120 wk2
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multivitamin
ip. injection of streptozotocin or vehicle
body weight, serum glucose
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HbA1c and serum insulin
Figure 1 Experimental protocol. Two day old neonatal male and female Wistar rats were injected with 100 mg/kg of streptozotocin (STZ)
(n = 69) or its vehicle (n = 38) to induce experimental diabetes mellitus. At week 4, fasting blood glucose measurement and an oral glucose
tolerance test (OGTT) were performed in order to verify the development of diabetes mellitus. Both non-diabetic (n = 38) and diabetic rats (n = 40)
were then fed with a mixture of vitamins, minerals, and trace elements (MVT or vehicle for eight weeks). Fasting blood glucose measurement was
performed in every second week and OGTT at week 4, 8 and 12 to monitor the effect of MVT treatment on diabetes mellitus. Serum insulin and
hemoglobinA1c level were measured at week 12 as well.
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To monitor the effect of MVT treatment on diabetes
mellitus, serum insulin levels were measured by an en-
zyme immunoassay (Mercodia, Ultrasensitive Rat Insulin
ELISA) in duplicates according to the manufacturer’s in-
structions as described [22].Measurement of serum cholesterol and triglyceride levels
Serum cholesterol and triglyceride levels were measured
with test kits supplied by Diasys Diagnostic Systems
(Holzheim, Germany) according to the instructions of
the manufacturer.Measurement of serum CRP level as a systemic
inflammatory marker
Serum CRP level was determined with a commercially
available immunturbidimetric kit from Roche Diagnos-
tics (Mannheim, Germany) according to the instructions
of the manufacturer.Measurement of serum ion concentrations
Serum calcium, magnesium, phosphate and iron ion
concentrations were measured with test kits from Roche
Diagnostics (Mannheim, Germany) according to the in-
structions of the manufacturer.Measurement of serum enzyme activities
Serum ASAT and LDH activities were measured in con-
trol placebo and diabetes placebo groups with kits from
Roche Diagnostics (Mannheim, Germany) according to the
instructions of the manufacturer.Statistical analysis
Statistical analysis was performed by using Sigmaplot
12.0 for Windows (Systat Software Inc). All values are
presented as mean ± SEM. Two way repeated measures
ANOVA was used to determine the effect of diabetes,
MVT, and the interaction of these two factors on body
weight, fasting blood glucose and glucose levels during
oral glucose tolerance test in the entire population as well
as in males or females, respectively. Two-Way ANOVA
was used to determine the effect of diabetes, MVT, and
the interaction of these two factors on glucose tolerance
test AUC, HbA1c and blood glucose in the entire popula-
tion as well as in males or females, respectively. After
ANOVA, all pairwise multiple comparison procedures
with Holm-Sidak post hoc tests were used as multiple
range tests. In case of serum triglyceride, cholesterol and
CRP levels, ion concentrations and enzyme activities, two
sample t-tests were used to determine statistical signifi-
cance between groups. P ≤ 0.05 was accepted as a statisti-
cally significant difference.
Table 1 Ingredients of the MVT preparation
Active ingredients Amount of ingredient/
1 g product
Daily dose*
Vitamin A1 (Retinol) 329 μg/g (1097 IU/g) 83.3 μg/kg/day
(278 IU/kg/day)
Vitamin B1 (Thiamin) 2.30 mg/g 0.58 mg/kg/day
Vitamin B2 (Riboflavin) 2.63 mg/g 0.67 mg/kg/day
Vitamin B3 (Nicotinamide) 11.8 mg/g 2.99 mg/kg/day
Vitamin B5 (Pantothenic acid) 3.95 mg/g 1.00 mg/kg/day
Vitamin B6 (Pyridoxine) 3.29 mg/g 0.83 mg/kg/day
Vitamin B12 (Cyanocobalamin) 3 μg/g 0.76 μg/kg/day
Folic acid 197 μg/g 49.9 μg/kg/day
Biotin 99 μg/g 25.1 μg/kg/day
Vitamin D3 (Cholecalciferol) 3 μg/g (120 IU/g) 0.76 μg/kg/day
(30.4 IU/kg/day)
Vitamin K1 (Phyllokinone) 26 μg/g 6.59 μg/kg/day
Rutoside 3.29 mg/g 0.83 mg/kg/day
Vitamin C 65.8 mg/g 16.7 mg/kg/day
Vitamin E 32.9 mg/g 8.33 mg/kg/day
Lutein 1.97 mg/g 0.50 mg/kg/day
Chrome 39 μg/g 9.88 μg/kg/day
Zinc 9.87 mg/g 2.50 mg/kg/day
Selenium 26 μg/g 6.59 μg/kg/day
Iron 2.63 mg/g 0.67 mg/kg/day
Iodine 66 μg/g 16.7 μg/kg/day
Manganese 0.66 mg/g 0.17 mg/kg/day
Copper 921 μg/g 233 μg/kg/day
Molybdenum 49 μg/g 12.4 μg/kg/day
Magnesium 65.8 mg/g 16.7 mg/kg/day
Calcium 132 mg/g 33.4 mg/kg/day
Phosphorus 102 mg/g 25.8 mg/kg/day
*To conform to the human daily dose of the preparation, rat daily dose was
adjusted according to the ratio of human and rat body surface areas.
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Figure 2 Body weight (panel a, n = 18-20) and fasting blood
glucose level (panel b, n = 18-20) in mixed genders. Values are
means ± SEM, *p < 0.05 control vs. diabetes; #p≤ 0.05 vehicle vs.
vitamin in case an interaction was found between the two factors
(control/diabetes and placebo/MVT).
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In order to verify the development of diabetes mellitus
in the STZ-treated rats, concentrations of several plasma
metabolites and body weight were measured at week 4
and during the treatment and follow-up period at week
6, 8, 10 and 12 (Figure 1). In the entire population of ex-
perimental animals of mixed genders, STZ-treated rats
showed lower body weight from week 8 to week 12, and
significantly increased fasting blood glucose at week 10
and 12 (Figure 2). In STZ-treated group, blood glucose
levels were significantly decreased by MVT treatment at
week 10 and 12 (Figure 2). However, male STZ-treated
rats showed a significant rise in fasting blood glucose
level at week 10 and 12 and a marked decrease in body
weight from week 6 to the end of the follow up period
(Figure 3a and c) showing the development of diabetesmellitus. Female STZ-treated rats failed to show elevated
serum fasting glucose level and reduced body weight
during the whole follow up period (Figure 3b and d).
Oral glucose tolerance test showed increased area under
the curve (AUC) in mixed genders, male and female in
STZ-treated rats at week 4, 8 and 12 showing impaired
glucose tolerance (Figures 4 and 5 and Table 2). MVT
treatment showed significant decrease in OGTT AUC
values at week 12 in case of mixed genders (Table 2). Sep-
arating the genders, multivitamin treatment decreased
significantly the OGTT AUC only in male STZ-
treated rats at week 8 and 12 proving an anti-diabetic ef-
fect of multivitamin treatment (Table 2). However, MVT
treatment did not change OGTT AUC in male control
rats (Table 2). Interestingly, AUC remained unchanged
by multivitamin treatment in female animals both in
STZ-treated and control groups as well as at week 8 and
12 (Table 2).
HbA1c level was significantly higher in STZ-induced
diabetes in mixed genders, as well as in males and females
respectively as compared to controls (Figure 6) at week
12. Interestingly, multivitamin treatment has significantly
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Figure 3 Body weight (panel a, n = 10-11in males and panel b, n = 8-9 in females) and fasting blood glucose level (panel c, n = 10-11
in males, panel d, n = 8-9 in females). Values are means ± SEM, *p < 0.05 control vs. diabetes; #p≤ 0.05 vehicle vs. vitamin in case an interaction
was found between the two factors (control/diabetes and placebo/MVT).
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#p≤ 0.05 vehicle vs. vitamin in case an interaction was found between the two factors (control/diabetes and placebo/MVT). Panel a demonstrates
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Figure 5 Blood glucose in males (n = 10-11) and females (n = 8-9) at week 4, 8 and 12. Values are means ± SEM, *p < 0.05 control vs.
diabetes; #p ≤ 0.05 vehicle vs. vitamin in case an interaction was found between the two factors (control/diabetes and placebo/MVT).
Panel a demonstrates blood glucose concentartions at week 4 in males, Panel b at week 8 in males, Panel c at week 12 in males,
Panel d at week 4 in females, Panel e at week 8 in females and Panel f at week 12 in females.
Table 2 OGTT AUC glucose values
OGTT AUC glucose
(min*mmol/L)
Control Diabetes* Week n
Vehicle MVT Vehicle MVT
Mixed genders 818 ± 22 821 ± 18 1615 ± 84 1539 ± 82 4 18-20
Mixed genders 895 ± 22 900 ± 21 1723 ± 76 1480 ± 86 8 18-20
Mixed genders 858 ± 13 866 ± 17 1942 ± 123 1596 ± 108# 12 18-20
Males 829 ± 24 846 ± 13 1754 ± 114 1613 ± 112 4 10-11
Males 940 ± 17 932 ± 24 1816 ± 126 1384 ± 74# 8 10-11
Males 868 ± 14 884 ± 25 2076 ± 195 1486 ± 130# 12 10-11
Females 808 ± 41 785 ± 37 1444 ± 102 1437 ± 118 4 8-9
Females 839 ± 38 857 ± 33 1609 ± 59 1597 ± 167 8 8-9
Females 846 ± 25 841 ± 12 1776 ± 75 1746 ± 181 12 8-9
Two Way ANOVA, *p < 0.05, Control vs. Diabetes including all groups in all time points, #p ≤ 0.05 vehicle vs. vitamin in case an interaction was found between the
two factors (control/diabetes and placebo/MVT).
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Figure 6 HbA1c levels in mixed genders (n = 18-20), males (n = 10-11) and females (n = 8-9) at week 12. Values are means ± SEM, *p < 0.05
control vs. diabetes; #p < 0.05 vehicle (Veh) vs. vitamin (Vit) (p = 0.097 vehicle vs. vitamin in both genders). #p ≤ 0.05 vehicle vs. vitamin in case an
interaction was found between the two factors (control/diabetes and placebo/MVT).
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http://www.biomedcentral.com/1472-6823/14/72reduced HbA1c level only in STZ-treated males without
having any effect in STZ-treated females and control ani-
mals in both genders (Figure 6).
Serum insulin concentration was significantly decreased
in STZ-treated animals proving beta cell damage (Figure 7).
MVT treatment showed a statistically not significant in-
creasing tendency in STZ-treated animals (Figure 7). Sep-
arate evaluation of the data of the genders revealed that
multivitamin treatment improved serum insulin level in
STZ-treated males; however, serum insulin levels remainedSe
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Figure 7 Serum insulin levels in mixed genders (n = 18-20), males (n =
*p < 0.05, control vs. diabetes; #p < 0.05 vehicle (Veh) vs. vitamin (Vit). No in
and placebo/MVT).unaffected by the multivitamin treatment in control males
(Figure 7). Neither diabetes mellitus, nor multivitamin
treatment had a significant effect on serum insulin levels
in female animals (Figure 7).
Serum triglyceride, cholesterol and CRP levels, ion con-
centrations including calcium, magnesium, phosphate and
iron, and LDH and ASAT enzyme activities were not sig-
nificantly altered in response to diabetes in either gender
in our present study (Additional file 2) in contrast to some
literature data [24,25].Male Female
Control Diabetes
Veh Vit Veh Vit
Diabetes
Veh Vit
*
10-11) and females (n = 8-9) at week 12. Values are means ± SEM,
teraction was found between the two factors (control/diabetes
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Here we have shown that chronic treatment with an MVT
preparation improved well established diagnostic markers
of diabetes such as fasting blood glucose, HbA1c, glucose
tolerance, and serum insulin levels in male diabetic rats.
Furthermore, we have shown here that females developed
a less severe prediabetic-like phenotype in response to
neonatal STZ-treatment as only OGTT was impaired and
HbA1c was increased. In the female animals, the MVT
preparation failed to attenuate the progression of diabetes
significantly. This is the first demonstration, that an MVT
preparation attenuates the progression of experimental
diabetes in males but not in females, which may suggest a
gender difference in the pathogenesis of diabetes.
Regular consumption of MVT preparations as food sup-
plements or medical food for diabetics is common in
developed countries. However, surprisingly preclinical or
clinical evaluation of such preparations is not available in
the literature. Therefore, here we evaluated the effect of
chronic treatment with an MVT preparation containing
15 vitamins and vitamin-like substances such as lutein
and rutoside, 3 minerals, and 8 micro/trace elements in
experimental diabetic rats. The MVT preparation showed
beneficial effects on major markers of diabetes in male but
not in female rats in the present study. This is the first evi-
dence in the literature that a complex MVT preparation
developed for human consumption significantly delayed
progression of diabetes in an animal model. The reason
why the MVT preparation was ineffective in female rats is
not known, however, it should be emphasized that female
rats developed only an impaired glucose tolerant state
characterized by an increased OGTT AUC and HbA1c
levels in the present study. It is well known that the
progression of diabetes occurs at a later age and be-
comes milder in females compared to age-matched males
in rodent models of diabetes (see for review [26]). One
may speculate that this could be one of the reasons why
the MVT preparation used in our present study was un-
able to improve the biochemical markers of early diabetes
significantly.
In our present study, neonatal STZ treatment in rats
resulted in a condition that was more similar to T1DM
than to T2DM. However, it has been shown in the litera-
ture that neonatal rats injected with streptozotocin devel-
oped acute diabetes followed by a spontaneous remission
due to some pancreatic β-cell regeneration. Therefore,
there is no total insulin deficiency, but a decreased serum
insulin concentration in STZ-treated animals [27-29]. Our
present study is in accordance with these literature data,
because serum insulin concentration was significantly
lower in males and mixed genders in STZ-treated animals
at week 12 (Figure 7). The literature is limited on the
effect of different individual minerals and vitamins or
related gender differences on pancreatic beta cellregeneration in diabetes. However, there are some
well-known vitamins and minerals including vitamin B3
and D as well as calcium ion that have been previously
linked to β-cell regeneration in diabetes. Vitamin B3 has
been shown to stimulate β-cell regeneration in partially
pancreatectomized rats [30,31], lengthen the “honeymoon”
period in type 1 diabetic patients [30,32], and improve in-
sulin secretion from patients at high risk of developing
type 1 diabetes [30,33]. Nicotinamide also protects β-cells
from streptozotocin-induced damage in rodents through
a suggested mechanism involving inhibition of PARP
[30,34-36]. Recently, vitamin D is thought to have benefi-
cial effects on pancreatic beta-cell dysfunction possibly via
both vitamin D receptor-dependent and -independent ac-
tions in diabetic patients of both genders [37]. In addition,
Ca2+ depletion has been shown to decrease β-cell prolifer-
ation and increase β-cell death by apoptosis [38]. These
studies, in agreement with our present findings, may sug-
gest that the multivitamin preparation beneficially affects
β-cell regeneration in male rats in our present study;
however, this potential effect should be investigated in
further studies.
In different experimental diabetes models and clinical
studies involving limited number of patients, several data
are available on the effect of individual vitamins, min-
erals, trace elements, or the combination of limited
number of them. The individual components of the
MVT preparation investigated in the present study were
selected by the manufacturer on the basis of their pre-
clinical and clinical data in different diabetic animal
models or patient populations. Daily doses of all compo-
nents of the preparation were set below the human
upper safe level [39].
Effects of individual vitamins on diabetes and/or its
complications have been investigated in a number of
preclinical and clinical trials. It was demonstrated that a
2-week administration of vitamin B1 in a high dose (0.2%
thiamin in drinking water) prevents diabetes-induced car-
diac fibrosis without reducing the blood glucose level in
male diabetic rats [7]. A randomized double-blind vehicle-
controlled clinical pilot study recruiting 40 type 2 dia-
betics with microalbuminuria demonstrated that a
high-dose vitamin B1 therapy (300 mg/day) for 3 months
produced a regression of urinary albumin excretion with-
out any effect on plasma glucose or HbA1c levels [40].
Vitamin D deficiency is a known risk factor of diabetes
mellitus. A double-blind parallel group vehicle-controlled
randomized trial involving 87 type 2 diabetics reported
that a single large dose (100,000 IU) of vitamin D2 im-
proved endothelial function 8 weeks after the administra-
tion, however, HbA1c and HOMA-IS were unaffected by
vitamin D2 therapy [41]. Additionally, another random-
ized, vehicle-controlled clinical trial with 81 participants
showed that vitamin D3 supplementation (4000 IU) for
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fasting insulin level in type 2 diabetic women [11].
A number of preclinical and clinical trials have investi-
gated the effects of individual minerals on diabetes and/
or its complications. A randomized controlled, single-
blinded trial with 31 patients demonstrated that oral
calcium supplementation (1500 mg/day) for 2 months
improves insulin sensitivity in patients with type 2 diabetes
and hypertension, however, both fasting blood glucose and
HbA1c levels were unaffected by the calcium supplemen-
tation [42]. Furthermore, it was shown that dietary calcium
supplementation (600 mg/day) for 3 months significantly
reduced vascular resistance and induced partial regression
of left ventricular hypertrophy in hypertensive non-insulin-
dependent diabetic Afro-Americans [13]. A clinical ran-
domized double-blind vehicle-controlled trial recruiting 63
type 2 diabetic patients with hypomagnesemia receiving
glibenclamide has shown that supplementation of magne-
sium (2.5 g MgCl2/day) for 4 months improved HbA1c,
fasting glucose as well as insulin levels [43]. Another
double-blind vehicle-controlled clinical trial enrolling 82
diabetic hypertensive adults with hypomagnesemia receiv-
ing captopril demonstrated that oral magnesium supple-
mentation (2.5 g MgCl2/day) for 4 months significantly
reduced fasting plasma glucose as well as HbA1c levels,
systolic and diastolic blood pressure [14]. In contrast, a
randomized clinical study involving 97 patients showed
that chronic supplementation of magnesium (300 mg/day)
for 5 years attenuated the evolution of polyneuropathy in
type 1 diabetics with magnesium deficiency without redu-
cing HbA1c level [44].
Limited number of clinical data on some individual
trace elements has shown beneficial effects on diabetes
and its complications. A clinical pilot study involving 22
patients demonstrated that zinc supplementation (30 mg/
day) for 3 months decreased lipid peroxidation in type 1
diabetes mellitus [45]. A prospective double-blind vehicle-
controlled crossover study involving 30 participants dem-
onstrated that supplementation of chromium for 2 months
significantly reduced serum triglyceride level in type 2 dia-
betic patients without any effect on serum glucose level
[46]. In contrast, another randomized clinical study in-
volving 180 patients with type 2 diabetes showed that
chromium administration (1000 μg/day) for 4 months had
beneficial effects on HbA1c, glucose, insulin, and choles-
terol variables [16].
Limited data on combinations of few numbers of vita-
mins, minerals and trace elements have shown beneficial
effects on diabetes and/or its cardiovascular complications.
A randomized, double-blind, vehicle-controlled clinical
trial showed that a combination of 200 mg magnesium,
30 mg zinc, 200 mg vitamin C, and 100 IU vitamin E sig-
nificantly improved glomerular function [6], blood pres-
sure [47] and increased HDL-c and apo A1 level [47]without beneficially affecting serum glucose and HbA1c
levels in 69 patients with type 2 diabetes mellitus after
3 months daily treatment. A randomized clinical trial en-
rolling 64 children with recent onset of type 1 diabetes
(IMDIAB IX) demonstrated that implementation of insu-
lin therapy with vitamin B3 (25 mg/kg body weight) alone
or in combination with vitamin E (15 mg/kg body weight)
for 2 years preserved baseline C-peptide secretion without
any effect on HbA1c level [48]. In contrast, a vehicle-
controlled double-blind randomized clinical trial involv-
ing 348 participants has reported that statin therapy
co-supplemented with biotin (2 mg/day) and chro-
mium (600 μg/day) for 3 months has significantly de-
creased serum glucose, HbA1c, LDL-cholesterol, total
cholesterol, and VLDL-cholesterol levels in type 2 diabetic
patients [49]. In many of the abovementioned studies
[6,11,40,41,45,47,49], some of the individual vitamins,
minerals and trace elements were used in a daily dose
above the upper safe level [39]. A pilot clinical study
in Sri Lanka involving 96 patients demonstrated that a 15-
component MVT preparation significantly reduced serum
glucose and lipid levels in adult diabetic patients after
4 months of supplementation [36], however, the daily dose
of 3 components of this preparation was above the upper
safe level and no gender difference was investigated [50].
The limitation of the present study is that it does not
provide evidence on the mechanism of the effect of the
MVT preparation and the individual contribution of the
26 components to the anti-diabetic effect of the prepar-
ation. The potential interactions of these components
and their combined effect rather than a single compo-
nent could be responsible for the beneficial effects of the
MVT preparation on the severity of diabetes. However,
investigation of the effects of each components and their
different variation of combinations was out of the scope
of the present study.
Conclusion
Although MVT preparations are widely used by dia-
betics, our present study is the first demonstration that a
MVT preparation attenuates the progression of experimen-
tal diabetes. Moreover, it seems that there is a gender differ-
ence in the development of diabetes and the anti-diabetic
effect to MVT treatment. Further studies are needed to
optimize the composition and to elucidate the efficacy,
safety and the mechanism of the effect of MVT prepara-
tions in diabetics.
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